Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
NeXT Personal® utilizes a Whole-Genome sequencing approach paired with advanced analytics and a comprehensive personalized signature. The NeXT Personal® methodology enables higher sensitivity without compromising specificity.1,2
Gain the potential to detect cancer recurrence earlier than imaging.2
Dr. James R. Black, MD, from UCL, London, UK discusses data demonstrating the utility of NeXT Personal to stratify low and high risk patients pre-operatively. Lung TRACERx is one of the most robust prospectively collected observational ctDNA studies for early-stage non-small cell lung cancer (NSCLC) with 170+ patients in the NeXT Personal cohort collected with median 5 years of follow-up, analyzed retrospectively.
⦁ Detected up to 4X as many patients with disease as previous generation assays in a low-shedding cancer ⦁ 100% baseline detection rate in non-LUAD
Limit of blank (LOB): 0.72 PPM The level of signal (noise) detected in instances where no tumor is present.
Detection threshold: 1.67 PPM in this study. The lower limit at which a positive call can be made at the defined specificity; defines LOD50.
95% Limit of detection (LOD95): 3.45 PPM The concentration at which 95% of readings would be positively detected.
Limit of quantification (LOQ): 10 PPM The lower limit at which two measurements can be quantitatively distinguished.
Analytical range: 10 PPM – 300,000 PPM The range over which two measurements can be quantitatively distinguished.
Detected down to ~1 PPM (LOD50)1
>99.98% analytical specificity through NeXT SENSE noise suppression engine1
4mL plasma and 1 mm3 FFPE tissue1*
*as low as 2ng cfDNA
One sample delivers MRD detection & tissue biomarkers
You can combine NeXT Personal MRD and optional variant tracking in our single platform
Core
Does the patient still have cancer? Is the patient responding to therapy?
Add-On
An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma
PRO-1121-v1
